The Technical Analyst
Compass Therapeutics, [CMPX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Compass Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.36% $1.490
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 189.95 mill |
| EPS: | -0.330 |
| P/E: | -4.52 |
| Earnings Date: | Mar 21, 2024 |
| SharesOutstanding: | 127.49 mill |
| Avg Daily Volume: | 0.376 mill |
| RATING 2024-04-22 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.52 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.77x |
| Company: PE -4.52 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.304 (-79.58%) $-1.186 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.311 - 1.669 ( +/- 12.01%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-08 | Boylan James P | Buy | 40 000 | Stock Option (Right to Buy) |
| 2024-02-09 | Gray Mary Ann | Buy | 40 000 | Stock Option (Right to Buy) |
| 2024-02-09 | Lindahl Richard S | Buy | 40 000 | Stock Option (Right to Buy) |
| 2024-02-09 | Gordon Carl L | Buy | 40 000 | Stock Option (Right to Buy) |
| 2024-02-09 | Chiniara Ellen | Buy | 40 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 93.96 |
| Last 94 transactions |
| Buy: 28 287 388 | Sell: 226 920 |
Forecast:
16:00 - $1.490
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.490
Forecast 2: 16:00 - $1.490
Forecast 3: 16:00 - $1.490
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.490 (1.36% ) |
| Volume | 0.101 mill |
| Avg. Vol. | 0.376 mill |
| % of Avg. Vol | 26.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CMPX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 12 - 12:31 | buy | $1.795 | N/A | Active |
|---|
CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-12 08:00:00 - Press Release
Compass Therapeutics Announces Poster Presentations At The Cholangiocarcinoma Foundation 2024 Annual Conference
Boston, april 12, 2024 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on ctx-009, the company's bispecific dll4/vegf-a antibody, at the cholangiocarcinoma foundation (ccf) 2024 annual conference to be held at the salt palace convention center in salt lake city, utah from april 17–19, 2024.
2024-04-10 08:00:00 - Press Release
Compass Therapeutics To Participate In The Stifel Targeted Oncology Days
Boston, april 10, 2024 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the company will participate in the stifel targeted oncology days taking place virtually april 16 – 17, 2024.
2024-04-09 12:00:00 - Press Release
Compass Therapeutics Presents Data Demonstrating Elimination Of Mhc Class I Negative Tumors In In Vivo Models At The 2024 American Association For Cancer Research (aacr) Annual Meeting
Boston, april 09, 2024 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today presents a poster on the combination of its bispecific antibody, ctx-009, and its agonistic anti-cd137 antibody, ctx-471, on anti-tumor activity in preclinical models at the 2024 american association for cancer research (aacr) annual meeting taking place at the san diego convention center in san diego, california on april 9.
2024-03-21 09:00:00 - Press Release
Compass Therapeutics Reports 2023 Financial Results And Provides Corporate Update
Enrollment in companion-002, the phase 2/3 randomized study of ctx-009 (dll4 x vegf-a bispecific antibody) in patients with advanced biliary tract cancer (btc), continues to progress well; top-line data from this study are expected by the end of 2024. enrollment in companion-003, the phase 2 study of ctx-009 in patients with advanced colorectal cancer (crc) was completed in the first quarter of 2024; top-line data from stage 1 of this study are expected by mid-year 2024.
2024-02-29 08:00:00 - Press Release
Compass Therapeutics To Participate In The Leerink Partners Global Biopharma Conference
Boston, feb. 29, 2024 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the company will participate in the leerink partners global biopharma conference in miami beach, florida on wednesday, march 13, 2024.
Latest News
2024-03-24 16:00:00 - InvestorPlace
3 Penny Stocks With the Power to 10X Your $1K Investment
Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger return.
2024-02-08 13:01:08 - Zacks Investment Research
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
Compass Therapeutics, Inc. (CMPX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-11-14 11:19:01 - Zacks Investment Research
Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Compass Therapeutics, Inc. (CMPX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-11-22 08:00:00 - GlobeNewsWire
Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which is taking place at the Lotte New York Palace November 29 – December 1, 2022.
2022-11-08 08:00:00 - GlobeNewsWire
Compass Therapeutics to Present at Upcoming Investment Conferences
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will be presenting at the following investor conferences during the month of November 2022.
2022-09-09 08:00:00 - GlobeNewsWire
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the Company will participate in the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place in New York City September 12 – 14, 2022.
2022-05-23 08:00:00 - GlobeNewsWire
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, is presenting virtually at the 2022 H.C. Wainwright Global Investment Conference, occurring May 23-26th, 2022.
2022-05-03 16:01:00 - GlobeNewsWire
Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009
2022-01-07 09:00:00 - Business Wire
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics, Inc. (Nasdaq: CMPX) will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on Wed., Jan. 12, 2022.
2021-11-22 10:00:00 - Business Wire
Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)---- $CMPX #CMPX--Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference